SCHEMBL6470340

SCHEMBL6470340

COc1cc2nc(Nc3nc(O)c4cc(OCCN(C)Cc5ccncc5)ccc4n3)nc(C)c2cc1OC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 1/20 0.41
KDM4E B2RXH2 3/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
TSHR P16473 2/20 0.37
BCHE P06276 1/20 0.37
ACHE P22303 1/20 0.37
KDM1A O60341 1/20 0.36
EHMT2 Q96KQ7 1/20 0.36
RCOR1 Q9UKL0 1/20 0.36
MAPT P10636 4/20 0.36
TP53 P04637 2/20 0.36
POLB P06746 2/20 0.36
BLM P54132 1/20 0.36
HSD17B10 Q99714 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
ALDH1A1 P00352 2/20 0.36
PSMD14 O00487 1/20 0.36
APAF1 O14727 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL6468643 0.85 MEN1 (0.38) KDM4EBCHEACHEHSD17B10MEN1
SCHEMBL6467448 0.84 ADRB2 (0.40) KDM4ETSHRMAPTTP53POLB
SCHEMBL6468013 0.84 KDR (0.41) KDM4EMAPTNPSR1MEN1KMT2A
SCHEMBL6470577 0.82 NPSR1 (0.43) KDM4ESMN1; SMN2TSHRMAPTTP53
Trifluoroacetic Acid SCHEMBL6465626 0.82 CSF1R (0.39) KDM4ESMN1; SMN2EHMT2MAPTTP53
Trifluoroacetic Acid SCHEMBL6469711 0.81 RET (0.39) KDM4ESMN1; SMN2KDM1AEHMT2RCOR1
SCHEMBL6470339 0.80 BRAF (0.40) BRAFKDM4ESMN1; SMN2TSHRMAPT
SCHEMBL6469542 0.79 NPSR1 (0.55) KDM4ESMN1; SMN2TSHRMAPTTP53
Trifluoroacetic Acid SCHEMBL6467968 0.78 KDR (0.41) KDM4EMAPTMEN1KMT2AALDH1A1
SCHEMBL6470079 0.78 NPSR1 (0.42) KDM4ESMN1; SMN2TSHRMAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections REPLIDYNE, INC. 2005-06-09 US claimed
WO-2005030131-A2 BIS-QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS REPLIDYNE, INC (US) 2005-04-07 WO claimed
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections REPLIDYNE, INC. 2005-06-09 US disclosed
WO-2005030131-A2 BIS-QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS REPLIDYNE, INC (US) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections POLI, POLK, POLB BRAF 2434/4885KDM4E 3225/4885SMN1; SMN2 4360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.